title: Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression Summary.
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA; ASCO, Alexandria, VA; University of Michigan, Ann Arbor, MI.
authors.forename: Harold J
authors.initials: HJ
authors.lastname: Burstein
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA; ASCO, Alexandria, VA; University of Michigan, Ann Arbor, MI guidelines@asco.org.
authors.forename: Christina
authors.initials: C
authors.lastname: Lacchetti
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA; ASCO, Alexandria, VA; University of Michigan, Ann Arbor, MI.
authors.forename: Jennifer J
authors.initials: JJ
authors.lastname: Griggs
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D010053:Ovary / Q000187:drug effects; D047648:Perimenopause; D011960:Receptors, Estrogen / Q000378:metabolism*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D011960:Receptors, Estrogen